What is the role of nonselective beta2-agonists for the treatment of status asthmaticus?

Updated: Jun 17, 2020
  • Author: Constantine K Saadeh, MD; Chief Editor: John J Oppenheimer, MD  more...
  • Print

Patients whose bronchoconstriction is resistant to continuous, handheld nebulizer treatments with traditional beta2-agonists may be candidates for nonselective beta2-agonists (eg, epinephrine [0.3-0.5 mg] or terbutaline [0.25 mg]) administered subcutaneously. [26] However, systemic therapy has no proven advantage over aerosol therapy with selective beta2 agents.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!